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the combination of ceftriaxone and amikacin is less costly than 
ceftazidime plus amikacin, piperacillin/tazobactam plus amikacin, 
and meropeneni. However, it should be stressed that the choice of 
antibiotic regimen should be based primarily on clinical and 
epidemiologic considerations; that is, in a setting of high risk of 
Pseudomonas aeruginosa infections, an antipseudomonal beta-lactam 
antibiotic should be preferred. 
New aspects of cystic fibrosis, lung infection 
and inflammation 
Defensins in cystic fibrosis (CF) 
J.-M. Schroeder. Department gDermatology, University o f  Kiel, Kiel, 
Germany 
Because Pseudomonas aeruginosa represents an imminent threat to 
patients with CF but not healthy persons, we addressed the question 
what keeps normal lungs fkee of I! aeruginora infection. Based on the 
working hypothesis that lung epithelial cells secrete I! aeruginosa 
killing peptide antibiotics, we isolated from supernatants of I? 
aeruginosa-stimulated lung epithelium cell line US49 a 4-kDa I? 
ueruginosa killing peptide, which is identical to human O-defensin 2 
(hBD-2), a defensin we recently discovered in inflamed skin. Natural 
hBD-2 strongly killed I? aeruginora (LDy":lOmg/L), but not 
Staphylococcus aureus (growth inhibition at concentration 100 mg/L). 
In contrast to all known human defensins, hBD-2 synthesis is 
inducible in epithelial cells by contact with bacteria or pro- 
inflammatory cytokines, which is supported by analyses of the 
promoter region of the hBD-2 gene. Because in CF it is believed that 
increased NaCI concentrations may affect antimicrobial activity of 
endogenous peptide antibiotics, we investigated the salt sensitivity of 
hBD-2 and found a dose-dependent inhibition of I? aeruginosa killing 
activity (I&: -80 mM), inmcating that hBD-2 is salt sensitive at 
physiologic ion strength. Investigation for hBD-2 in sputum of CF 
patients revealed immunoreactive hBD-2, indicating that hBD-2 
production is not defective in CF. Systematic screening of CF 
patients' sputum for antimicrobial activity, however, revealed-apart 
from known defensins 1-3 and lysozyme-a number of as yet not 
identified molecules that might be important in antimicrobial defense 
in CF. 
Epithelial cell interactions involving CFTR and 
bacterial pathogens 
G. Pier. Hurvard Medical School, Channing Laboratory, Boston, MA, 
USA 
The CF transmembrane conductance regulator (CFTR) plays a 
critical role a$ a receptor involved in the lung's response to Pseudo- 
moms aeruginosa. The absence of CFTR protein in most severe cases 
of CF results in decreased clearance of I! aeruginosa from the lung in 
the early stages of infection. We have recently determined that under 
the right conditions CF mice are hypersusceptible to oropharyngeal 
colonization by I! aeruginora from environmental sources as well as 
experimentally induced I? aeruginora lung infection. All mice exposed 
to I) aeruginosa in drinking water become colonized in the 
oropharynx, but once the contaminated water is removed, both wild- 
type and heterozygote *F508 Cftr mice clear the colonization, 
whereas CF mice remain colonized for prolonged periods. Intro- 
duction of I) aeruginosa enmeshed in alginate beads into the lungs of 
CF mice results in long-term infection accompanied by significant 
changes in pulmonary obstruction, whereas mice with at least one 
wild-type Cftr gene clear this infection. CFTR is also utilized by 
Salmonella typhi as a receptor for translocation from the gastro- 
intestinal tract. Recent stumes in CF mice with a G551 D allele 
indicate that this Cftr mutation results in decreased uptake of both S. 
typhi and I? aeruginosa by homozygote G551 D and heterozygote 
G551 D mice compared with wild-type mice. This is identical to 
results reported for *F508 Cftr mice. Overall, CFTR is an important 
receptor for both I? aeruginosa and S. typhi, and changes in CFTR 
protein due to mfferent gene mutations can result in a similar pheno- 
type in regard to susceptibility and resistance to I? aeruginosa and S. 
typhi infections. 
Neutrophil-parasite interactions 
N. Hoiby. Department of Clinical Microbiology 9301 G Danish Cystic 
Fibrosis Center, Copenhagen, Denmark 
Most patients with cystic fibrosis (CF) suffer from chronic endo- 
bronchial Pseudomonas aeruginosa infections. The lung tissue damage 
is caused by continuous activation of the immunologically specific 
inflammatory defense mechanisms of the lungs initiated by the anti- 
body response and dominated by polymorphonuclear neutrophil 
leukocytes and their proteolytic and oxidative products. This inflam- 
mation induces a phenotypic shift from non-mucoid to mucoid, 
alginate-producing phenotypes of I! aeruginosa which then grow as a 
biofilm endobronchially. Such biofilms are impossible to eradicate 
with antibiotics. Currently used treatment strategies are chronic 
suppressive antibiotic treatment against I! aeruginora and use of anti- 
inflammatory drugs such as inhaled budesonide or systemic treatment 
with ibuprofen or piroxicam. The immune response responsible for 
the tissue damage mimics a Th2 response, and animal experiments 
suggest that a shift to a Thl-like response by, for example, gamma- 
interferon treatment, may delay the tissue damage. Clinical trials have, 
however, not yet been carried out with gamma-intexferon treatment. 
182421 Bacterial vaccines in cystic fibrosis 
G. Doering. Hygiene-Institute, University of Tuebingen, Tuebingen, 
Germany 
In patients with cystic fibrosis (CF), Preudomonas aeruginosa and 
Staphylococcus aureus cause chronic pulmonary infections which are 
difficult to treat with antibiotics. Loss of lung function is the major 
cause of death in CF. Vaccination is a possible way to prevent these 
infections, and several antigens, including I? aeruginosa flagella and S. 
aureus exopolysaccharides, are promising vaccine candidates. In vitro 
and animal studies showed that flagella antigens were protective in 
compromised animals. Phase 1 studies using Immuno s flagella 
vaccines in healthy individuals and CF patients revealed that these 
vaccine preparations were well tolerated, showed no adverse side 
effects and gave rise to high and long-lasting antibody titers in the 
circulation of the individuals. Furthermore, immunization with a 
flagella vaccine elicited specific anti-flagellar antibodies not only 
systemically, but also in the secretory immune system of the airways. 
Consequently, a phase Ill multicenter vaccine trial using the I? 
aeruginosa 5142/1210-Flagella Vaccine IMMUNO was initiated. The 
study design is placebo-controlled, randomized and double-blind, 
involving about 500 CF patients without I? aeruginosa lung infection 
in 25 European CF centers. 
